StockData
ArriVent BioPharma, Inc. logo

ArriVent BioPharma, Inc. (AVBP) shareholders

AVBPNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 8/30
$10.69−0.87 (-7.53%)

Close on Nov 17, 2026Market cap $527.10MP/E –Yield –

Ownership

Institutional holdings as of Jun 30, 2026, from 13F filings

Held by institutions
93.5%
46M of 49M shares
Institutional holders
158
36 new, 15 sold out
Net institutional buying
4M
In Q2 2026
Insider trades, 12 months
0 buys · 1 sales
Net sold $12.98M

Shares held by institutions

Holders of more than 5%

Latest Schedule 13D (active) or 13G (passive) filed by each holder

HolderShares% of classFilingAs of
HHLR Advisors, Ltd.
Joint filing with Hillhouse Investment Management, Ltd. (13.40%)
4,484,67213.40%13G (passive)Sep 30, 2024
Infinitum Cayman Master, Ltd.
Joint filing with Infinitum Asset Management, LLC (9.90%), Infinitum Partners GP, LLC (9.90%)
4,123,9239.90%13G (passive) amendmentDec 31, 2025
Hillhouse Investment Management, Ltd.3,929,1179.50%13G (passive) amendmentDec 31, 2025
Infinitum Cayman Master, Ltd. (Fund)
Joint filing with Infinitum Asset Management, LLC (9.90%), Infinitum Partners GP, LLC (9.90%)
3,418,9239.90%13G (passive)May 1, 2025
Suvretta Capital Management, LLC
Joint filing with Aaron Cowen (9.90%), Averill Master Fund, Ltd. (8.70%)
3,412,7889.90%13G (passive) amendmentJun 30, 2025
BlackRock, Inc.3,182,0806.80%13G (passive) amendmentJun 30, 2026
FMR LLC
Joint filing with Abigail P. Johnson (6.80%)
3,016,1326.80%13G (passive) amendmentMar 31, 2026
Orbimed Advisors LLC2,875,9625.80%13D (active) amendmentOct 6, 2026
Abigail P. Johnson
Joint filing with FMR LLC (5.80%)
2,863,3405.80%13G (passive) amendmentSep 30, 2026
Vivo Opportunity, LLC2,472,7015.00%13G (passive)Oct 6, 2026
HBM Healthcare Investments (Cayman) Ltd.2,195,0145.40%13G (passive)Oct 8, 2025
Yi Shi
Joint filing with LAV Fund VI, L.P. (“LAVVI”) (6.20%)
2,046,1236.40%13G (passive)Jan 26, 2024
Dr. Maha Katabi (“Katabi”)
Joint filing with Sofinnova Venture Partners XI, L.P. (“SVP XI”) (5.10%), Sofinnova Management XI, L.P. (“SM XI LP”) (5.10%) and 2 more
1,696,7525.10%13G (passive)Sep 30, 2024

Top institutional holders

13F holdings as of Jun 30, 2026

HolderShares% of AVBPValueChange% of portfolio
Suvretta Capital Management, LLC4,515,5319.16%$156.87M+114,4482.87%
Infinitum Asset Management, LLC4,438,3849.00%$154.19M+289,46115.68%
Hhlr Advisors, Ltd.3,929,1177.97%$136.50M–16.40%
BlackRock, Inc.3,250,3966.59%$112.92M+720,0950.00%
Orbimed Advisors LLC3,027,3286.14%$105.17M–1.95%
FMR LLC2,778,9595.64%$96.54M−237,1730.00%
Octagon Capital Advisors LP1,971,0544.00%$68.47M–6.15%
Vanguard Capital Management LLC1,774,8733.60%$61.66M+245,9800.00%
Sofinnova Investments, Inc.1,696,7523.44%$58.95M–3.05%
State Street Corp1,692,9863.43%$58.81M+271,5710.00%
Vivo Capital, LLC1,682,0973.41%$58.44M+796,1815.34%
Novo Holdings A/S1,500,0003.04%$52.11M−442,1423.03%
General Catalyst Group Management, LLC1,494,7863.03%$51.93M–27.55%
Logos Global Management LP1,000,0002.03%$34.74M+650,0001.50%
Geode Capital Management, LLC972,6261.97%$33.80M+168,9740.00%
D. E. Shaw & Co., Inc.872,0111.77%$30.29M+503,2160.01%
Goldman Sachs Group Inc853,7231.73%$29.66M+2960.00%
HSG Holding Ltd663,3081.35%$23.04M–1.85%
Point72 Asset Management, L.P.566,7961.15%$19.69M−181,3990.02%
Millennium Management LLC438,6640.89%$15.24M+12,7410.01%

Institutional buying and selling by quarter

Positions opened, added to, reduced and closed by 13F filers

QuarterHoldersShares held% of sharesNew / addedReduced / closedShares boughtShares sold
Q2 202615846M93.5%36 / 7230 / 156M2M
Q1 202613942M85.4%35 / 5828 / 177M3M
Q4 202512240M81.3%30 / 4135 / 145M3M
Q3 202510639M78.3%18 / 4718 / 116M1M
Q2 20259934M68.2%26 / 2530 / 95M1M
Q1 20258329M59.0%15 / 2922 / 112M1M
Q4 20248028M57.7%24 / 3312 / 113M1M
Q3 20246826M52.6%17 / 373 / 25M0M
Q2 20245422M43.9%12 / 228 / 111M2M
Q1 20245322M44.4%53 / 00 / 022M0M

Top mutual fund and ETF holders

Latest monthly portfolio reports (Form N-PORT)

139 funds held AVBP in Q2 2026, 56% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.

FundShares% of AVBPValue% of fundAs of
Select Biotechnology Portfolio1,439,8032.92%$43.58M0.83%May 31, 2026
Vanguard Total Stock Market Index Fund1,338,7642.72%$46.51M0.00%Jun 30, 2026
iShares Russell 2000 ETF984,7862.00%$34.21M0.04%Jun 30, 2026
State Street(R) SPDR(R) S&P(R) Biotech ETF880,4261.79%$30.59M0.28%Jun 30, 2026
Fidelity Small Cap Index Fund414,8720.84%$12.37M0.04%Jul 31, 2026
Vanguard Extended Market Index Fund397,0780.81%$13.79M0.01%Jun 30, 2026
iShares Russell 2000 Growth ETF350,0060.71%$12.16M0.08%Jun 30, 2026
Fidelity Growth Company Fund324,0400.66%$9.81M0.01%May 31, 2026
Fidelity Small Cap Growth Fund298,7400.61%$8.91M0.10%Jul 31, 2026
iShares Biotechnology ETF230,4870.47%$8.01M0.09%Jun 30, 2026
Vanguard Russell 2000 Index Fund165,7820.34%$5.02M0.03%May 31, 2026
Fidelity Extended Market Index Fund158,1900.32%$4.79M0.01%May 31, 2026
Fidelity Small Cap Growth K6 Fund149,0300.30%$4.44M0.10%Jul 31, 2026
Schwab U.S. Small-Cap ETF147,1280.30%$4.45M0.02%May 31, 2026
iShares Micro-Cap ETF127,0000.26%$4.41M0.29%Jun 30, 2026

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares owned% of sharesLatest filing
Stuart LutzkerPresident of R&D, Director147,7440.30%Feb 4, 2026
Zhengbin YaoPresident and CEO, Director613,1381.24%Feb 4, 2026
Robin LaChapelleChief Operating Officer570,9061.16%Nov 2, 2026
Winston KungChief Financial Officer––Feb 4, 2026
James Paul KastenmayerGeneral Counsel7,3860.01%Feb 4, 2026
John HohnekerDirector––Jun 22, 2026
Chris NoletDirector––Jun 22, 2026
Kristine PetersonDirector––Jun 22, 2026
Merdad ParseyDirector––Jun 22, 2026
Hhlr Advisors, Ltd.10% owner3,929,1177.97%Feb 3, 2026
Hillhouse Investment Management, Ltd.10% owner––Feb 3, 2026

Insider trades

Common stock transactions reported on Form 4, newest first

InsiderDateTransactionSharesPriceValueShares after
Robin LaChapelle
Chief Operating Officer
Oct 30, 2026Option exercise+17,648$6.24$110.05K176,429
Robin LaChapelle
Chief Operating Officer
Oct 30, 2026Option exercise+1,820$2.28$4.15K158,781
Robin LaChapelle
Chief Operating Officer
Oct 30, 2026Option exercise+4,550$2.28$10.38K156,961
Robin LaChapelle
Chief Operating Officer
Oct 30, 2026Option exercise+410$2.28$935152,411
Robin LaChapelle
Chief Operating Officer
Oct 30, 2026Option exercise+16,265$3.65$59.37K152,001
Hhlr Advisors, Ltd.
10% owner
Dec 10, 2025Sale−555,555$23.37$12.98M3,929,117
Robin LaChapelle
Chief Operating Officer
Jul 11, 2025Option exercise+2,600$2.28$5.93K129,233
Robin LaChapelle
Chief Operating Officer
Jul 11, 2025Option exercise+6,503$2.28$14.83K135,736
Robin LaChapelle
Chief Operating Officer
Jul 11, 2025Option exercise+2,050$2.28$4.67K126,633
Robin LaChapelle
Chief Operating Officer
Sep 19, 2024Option exercise+2,867$2.28$6.54K102,584
Robin LaChapelle
Chief Operating Officer
Sep 19, 2024Option exercise+2,700$6.24$16.85K99,717
Robin LaChapelle
Chief Operating Officer
Sep 19, 2024Option exercise+7,164$2.28$16.33K109,748
Robin LaChapelle
Chief Operating Officer
Sep 19, 2024Option exercise+12,364$3.65$45.13K124,583
Robin LaChapelle
Chief Operating Officer
Sep 19, 2024Option exercise+2,471$2.28$5.63K112,219
Hhlr Advisors, Ltd.
10% owner
Jan 30, 2024Conversion+3,616,041––3,616,041
Hhlr Advisors, Ltd.
10% owner
Jan 30, 2024Buy+555,555$18.00$10.00M4,484,672
Hhlr Advisors, Ltd.
10% owner
Jan 30, 2024Conversion+313,076––3,929,117
Carl L. Gordon
Director, 10% owner
Jan 30, 2024Buy+222,222$18.00$4.00M1,513,664
Carl L. Gordon
Director, 10% owner
Jan 30, 2024Conversion+821,827––821,827
Carl L. Gordon
Director, 10% owner
Jan 30, 2024Conversion+821,827––821,827
Carl L. Gordon
Director, 10% owner
Jan 30, 2024Conversion+469,615––1,291,442
Carl L. Gordon
Director, 10% owner
Jan 30, 2024Buy+222,222$18.00$4.00M1,513,664
Carl L. Gordon
Director, 10% owner
Jan 30, 2024Conversion+469,615––1,291,442
OrbiMed Asia GP IV, L.P.
Director, 10% owner
Jan 30, 2024Conversion+821,827––821,827
OrbiMed Asia GP IV, L.P.
Director, 10% owner
Jan 30, 2024Conversion+821,827––821,827
OrbiMed Asia GP IV, L.P.
Director, 10% owner
Jan 30, 2024Conversion+469,615––1,291,442
OrbiMed Asia GP IV, L.P.
Director, 10% owner
Jan 30, 2024Conversion+469,615––1,291,442
OrbiMed Asia GP IV, L.P.
Director, 10% owner
Jan 30, 2024Buy+222,222$18.00$4.00M1,513,664
OrbiMed Asia GP IV, L.P.
Director, 10% owner
Jan 30, 2024Buy+222,222$18.00$4.00M1,513,664
James Healy
Director
Jan 30, 2024Buy+444,444$18.00$8.00M1,696,752
James Healy
Director
Jan 30, 2024Conversion+1,252,308––1,252,308

Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of float
14.08%
6M shares short
Days to cover
3.4
At 2M shares a day
Change since last report
-14.8%
From 7M shares
Short volume, 20 days
47.3%
Of volume reported to FINRA

Shares sold short, last 12 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of ArriVent BioPharma's stock actually held short. Settlement fails (shares not delivered on time) peaked at 206,555 shares on Oct 7, 2026 over the last 90 days.

See a number that looks wrong?